wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q54274283-3C4902B5-4FD2-49BD-84F0-CDE6D8C41D6E
Q54274283-3C4902B5-4FD2-49BD-84F0-CDE6D8C41D6E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q54274283-3C4902B5-4FD2-49BD-84F0-CDE6D8C41D6E
[TKI Resistance for T790M Mutation].
P2860
Q54274283-3C4902B5-4FD2-49BD-84F0-CDE6D8C41D6E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q54274283-3C4902B5-4FD2-49BD-84F0-CDE6D8C41D6E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
84545941b8886e4ec72cd78ffc61db0bfe9657df
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.